- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01056861
Effects of Botulinum Toxin in Cervical Dystonia
Effects of Botulinum on the Afferent Input Modulation of Neuronal Circuits Involved in Cervical Dystonia
Botulinum toxin injection in the contracting muscles has proven to be a safe and effective method of relieving pain and lessening dystonic posturing. The current hypothesis is that botulinum toxin works on altering sensory input in the central nervous system in addition to its effects on the neuromuscular junction.
Magnetoencephalography (MEG)of brain has been used in dystonia such as writer's cramp and musician's hand dystonia. However, no study has investigated the correlation of central signal changes via magnetoencephalography before and after treatment with botulinum in torticollis patients. Prior studies using somatosensory potentials indicated the possibility of differential activation of precentral cortex in patients with cervical dystonia. Cervical dystonia may result from a disorder of both cortical excitability and intracortical inhibition. The investigators hypothesis is that botulinum injection modulates central inhibition which improves clinical outcome for torticollis.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- male or female subjects 18 years to 90 years
- females who are child bearing potential, with negative pregnancy testing, who are willing to use reliable form of contraception during the study
- subjects meeting the criteria for torticollis
Exclusion Criteria:
- intracranial metal objects generating significant magnetic artifact
- females who are pregnant, planning pregnancy, unable to use contraception
- mental instability
- any medical condition that may put the subject at increased risk with exposure to botulinum toxin, allergy or sensitivity
- significant head tremor
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Cervical dystonia (torticollis)
Subjects meeting the criteria fot torticollis who are receiving botulinum toxin injections.
|
Not exceeding a total dose of 400 units, once every three months.
Other Names:
|
|
Control
age matched controls with out cervical dystonia (torticollis)
|
Not exceeding a total dose of 400 units, once every three months.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Evidence of Cortical organizational changes with botulinum toxin treatment in patients with torticollis utilizing magnetoencephalography
Time Frame: two to eight weeks following treatment
|
two to eight weeks following treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Tsui Torticollis Rating scale
Time Frame: Two-eight weeks
|
Two-eight weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Naganand Sripathi, MD, Henry Ford Health System
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Movement Disorders
- Dyskinesias
- Dystonia
- Dystonic Disorders
- Torticollis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- Neuromuscular Agents
- Botulinum Toxins
- Botulinum Toxins, Type A
- abobotulinumtoxinA
Other Study ID Numbers
- 5307
- 08-0124 (Other Grant/Funding Number: Allergan1)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Dystonia
-
Fondation Ophtalmologique Adolphe de RothschildCompletedCervical Dystonia, PrimaryFrance
-
University Hospital, MontpellierTerminatedSpasticity | Isolated Cervical Dystonia | Complex DystoniaFrance
-
University of FloridaBachmann Strauss Dystonia & Parkinson Foundation, Inc.Completed
-
Universitätsklinikum Hamburg-EppendorfCompletedIsolated Cervical DystoniaGermany
-
Duke UniversityAmerican Academy of NeurologyEnrolling by invitation
-
Fondazione Don Carlo Gnocchi OnlusActive, not recruitingPrimary Cervical DystoniaItaly
-
University of Colorado, DenverCompleted
-
University of FloridaAmerican Brain Foundation; NeuroneticsCompletedDystonia | Primary Cervical DystoniaUnited States
-
University Hospital, LilleCompletedIdiopathic Cervical DystoniaFrance
-
IpsenCompletedIdiopathic Cervical DystoniaBelgium, France, United Kingdom, Portugal, Germany, Australia, Czechia, Netherlands, Russian Federation
Clinical Trials on Botulinum Toxin A
-
AllerganTerminatedOveractive BladderSerbia, Turkey, Greece, Egypt, Lebanon, India
-
Centre Hospitalier Universitaire de NīmesNot yet recruiting
-
Assiut UniversityNot yet recruitingSpasticity as Sequela of Stroke
-
Walter Reed Army Medical CenterUnknown
-
YangHuiUnknown
-
Daewoong Pharmaceutical Co. LTD.Completed
-
Mentor Worldwide, LLCSynteract, Inc.CompletedGlabellar RhytidesUnited States
-
AllerganCompletedOveractive BladderPortugal, South Africa, Netherlands, Canada, Singapore, Brazil, United States, Taiwan, Italy, United Kingdom, France, Spain
-
Mentor Worldwide, LLCSynteract, Inc.CompletedGlabellar Rhytides | Frown Lines Between the EyebrowsUnited States
-
AllerganCompletedOveractive BladderUnited Kingdom, Belgium, New Zealand, France, Russian Federation, Czech Republic, United States, Germany, Austria, Poland, Slovakia, Ukraine, Canada, Australia